Larvol Veri

BIOMARKER:

HRD

Related biomarkers:

‹

›

HRD HRD	Fallopian Tube Cancer Fallopian Tube Cancer	olaparib + bevacizumab Sensitive: A1 - Approval olaparib + bevacizumab Sensitive : C1
HRD HRD	Peritoneal Cancer Peritoneal Cancer	olaparib + bevacizumab Sensitive: A1 - Approval olaparib + bevacizumab Sensitive : C1
HRD HRD	Peritoneal Cancer Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : C1
HRD HRD	Fallopian Tube Cancer Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : C1
HRD HRD	Ovarian Cancer Ovarian Cancer	olaparib + bevacizumab Sensitive: A1 - Approval olaparib + bevacizumab Sensitive : C1
HRD HRD	Ovarian Cancer Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : C1
HRD HRD	Prostate Cancer Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : C1
HRD HRD	Ovarian Cancer Ovarian Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : C1
HRD HRD	Ovarian Cancer Ovarian Cancer	rucaparib Sensitive: B - Late Trials rucaparib Sensitive : B
HRD HRD	Ovarian Cancer Ovarian Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
HRD HRD	Ovarian Cancer Ovarian Cancer	atezolizumab Resistant: B - Late Trials atezolizumab Resistant : B
HRD HRD	Ovarian Cancer Ovarian Cancer	CPB Sensitive: B - Late Trials CPB Sensitive : B
HRD HRD	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
HRD HRD	Ovarian Cancer Ovarian Cancer	tislelizumab + BGB-290 Sensitive: C2 – Inclusion Criteria tislelizumab + BGB-290 Sensitive : C2
HRD HRD	Triple Negative Breast Cancer Triple Negative Breast Cancer	tislelizumab Sensitive: C2 – Inclusion Criteria tislelizumab Sensitive : C2
HRD HRD	Ovarian Cancer Ovarian Cancer	bevacizumab + niraparib Sensitive: C2 – Inclusion Criteria bevacizumab + niraparib Sensitive : C2
HRD HRD	Non Small Cell Lung Cancer NSCLC	talazoparib Resistant: C3 – Early Trials talazoparib Resistant : C3
HRD HRD	Gastric Cancer Gastric Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
HRD HRD	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab + niraparib Sensitive: C3 – Early Trials pembrolizumab + niraparib Sensitive : C3
HRD HRD	Prostate Cancer Prostate Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
HRD HRD	Prostate Cancer Prostate Cancer	abiraterone acetate Resistant: C3 – Early Trials abiraterone acetate Resistant : C3
HRD HRD	Ovarian Cancer Ovarian Cancer	ABT-767 Sensitive: C3 – Early Trials ABT-767 Sensitive : C3

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES